Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1631 1633 1799
This examiner grants 38% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18407298 | RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS | Non-Final OA | Genzyme Corporation |
| 17999762 | COMPOSITIONS AND METHODS FOR EPIGENOME EDITING | Non-Final OA | The Regents of the University of California |
| 17551030 | Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof | Final Rejection | The Regents of the University of California |
| 18065360 | MINI-PROMOTER | Non-Final OA | Vanderbilt University |
| 17763122 | NOTCH RECEPTORS WITH ZINC FINGER-CONTAINING TRANSCRIPTIONAL EFFECTOR | Non-Final OA | Trustees of Boston University |
| 18558919 | COMPOSITIONS AND METHODS RELATED TO THE TREATMENT OF OCULAR DISEASES IN EQUINES | Non-Final OA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 16761876 | METHODS AND COMPOSITIONS FOR CIRCULAR RNA MOLECULES | Final Rejection | The University of North Carolina at Chapel Hill |
| 14596051 | METHOD FOR INDUCING CELLS TO LESS MATURE STATE | Non-Final OA | Minerva Biotechnologies Corporation |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | Non-Final OA | Kite Pharma, Inc. |
| 18517080 | COMPOSITIONS AND METHODS OF TREATING USHER SYNDROME III | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18296623 | METHOD FOR GENERATING T CELLS PROGENITORS | Final Rejection | Institut National de la Santé et de la Recherche Médicale (INSERM) |
| 18191790 | AAV-BASED GENE THERAPY FOR MULTIPLE SCLEROSIS | Final Rejection | University of Florida Research Foundation, Incorporated. |
| 17178972 | GENERATING GABAergic NEURONS IN BRAINS | Non-Final OA | The Penn State Research Foundation |
| 17046807 | ANTI-AGING COMPOSITIONS AND METHODS OF USE | Final Rejection | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17769886 | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASE | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17260418 | LIPID PARTICLE CONTAINING A-TYPE CpG OLIGODEOXYNUCLEOTIDE | Non-Final OA | TEIKYO UNIVERSITY |
| 16933773 | NUCLEIC ACID PURIFICATION | Final Rejection | ZYMO RESEARCH CORPORATION |
| 16645213 | STEM CELL DERIVED FROM NEONATAL PIG AND METHOD FOR PRODUCING SAME | Final Rejection | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 17592335 | MRNA THERAPY FOR THE TREATMENT OF OCULAR DISEASES | Non-Final OA | Translate Bio, Inc. |
| 17897878 | LIPID NANOPARTICLE FORMULATIONS FOR CRISPR/CAS COMPONENTS | Final Rejection | Intellia Therapeutics, Inc. |
| 18041371 | CULTURED TISSUE AND BIOREACTOR SYSTEMS AND METHODS FOR PRODUCTION THEREOF | Non-Final OA | Trustees of Tufts College |
| 18173485 | METHODS FOR ENHANCING ANTI-TUMOR ACTIVITY OF EXHAUSTED T CELLS | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18486941 | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | Non-Final OA | TEAMEDON INTERNATIONAL, INC. |
| 18467037 | TRANS-SPLICING METHODS AND COMPOSITIONS FOR GENERATION OF SINGLE SEX OFFSPRING | Non-Final OA | JFL CAPITAL MANAGEMENT, LLC |
| 16924158 | RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION | Final Rejection | ethris GmbH |
| 18336276 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | Non-Final OA | Amicus Therapeutics, Inc. |
| 18156184 | Oncolytic Vaccinia Virus | Final Rejection | Queen Mary University of London |
| 18134383 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION AND DISCOGENIC BACK PAIN | Final Rejection | KOLON TISSUEGENE, INC. |
| 18134401 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION AND DISCOGENIC BACK PAIN | Final Rejection | Kolon Tissuegene, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy